Regenexx C

Regenexx C is an autologous cultured mesenchymal stem cell therapy developed by Regenerative Sciences for orthopedic indications such as osteoarthritis and other musculoskeletal injuries. The procedure involves harvesting a patient's mesenchymal stem cells, typically from bone marrow and in some descriptions also synovial fluid, expanding the cells ex vivo in autologous platelet lysate, and reinjecting the culture-expanded cell product into the site of injury. Its intended mechanism is regenerative and paracrine rather than receptor-specific pharmacology, with the expanded autologous cells expected to support tissue repair, modulate local inflammation, and promote healing in damaged joints, discs, tendons, or related orthopedic tissues. Regenexx C was the subject of FDA enforcement in the United States and, following a 2014 court ruling that treated the cultured product as a drug requiring FDA approval, it is no longer offered in the United States and has been offered through Regenexx Cayman.

Brand names

Regenexx C

Other names

Regenexx-Ccultured autologous mesenchymal stem cell procedure